Work(13)
(  )
Industry:
Scroll

1910

Visual
(13)
eloquence.

NEXT FRAME( 6 )

More work, still
taking shape.
Open
we use cookies
Decline
Accept
F/S ©2026
INTEGRITY THROUGH EXPRESSION™
sound
off
INTEGRITY THROUGH EXPRESSION™ ©16/26
1910
  • Industry:
    AI Drug Discovery, Biotech
  • Country:
    U.S.A.
  • Timeline:
    5 months
  • Service(s):
    17
    1. Competitive Analysis
    2. Creative Direction
    3. Art Direction
    4. Brand Identity
    5. Brand Application
    6. Design System
    7. Photography Art Direction
    8. Videography Art Direction
    9. Pitch Deck Design
    10. Graphic Design
    11. Illustration
    12. 3D Visualization
    13. Video & Motion
    14. Web UX Design
    15. Web UI Design
    16. Webflow Development
    17. Content Management System
  • Sector:
Overview Objectives Approach Results

Founded in 2018 in Boston, 1910 Genetics (biotech) began with two AI platforms, ELVIS for small molecule drugs and ROSALYND for protein therapeutics, and one aim: "to make undruggable targets a thing of the past".

In 2026 it relaunched as 1910 and put the platform to work across pharma, as "an infrastructure for AI-enabled drug discovery". The stated ambition goes further: to make every pharma company an AI company.

  1. Reposition a company that had proven its platform as one that now deploys it, for pharma partners.
  2. Bring technical credibility into the first meeting: an entry point built for enterprise sales and big pharma.
  3. Explain a platform in three parts through visual storytelling, without drifting into the science, for a business development reader with ten minutes and a mandate.

The second engagement started where the first ended, with a different company: a new offering, a new positioning and everything rebuilt from the start, colour, symbol and system, while the core message and the founding vision stayed. The technology would no longer be explained in an image and a short clip; it would be walked through, component by component, each backed by the scientific logic and the proof behind it. The look and feel: an enterprise-grade company, confident in the rooms it now enters.

A new identity, the website, the founder video and the full explainer of the ITO™ platform in its three parts, AI-driven Precision Target ID, AI-driven Molecular Design & Optimization and Federated Learning, launched in February 2026, five years after the studio's first brand and website for the company.

That earlier engagement launched in late 2020; the following March the company debuted publicly with $26M, per GlobeNewswire. From there the company went on to $40M in all, across seed, Series A and Series A-2, per its investor page, and came to 2026 with a platform proven and a position to take.

Visit Website

01:32

Play

The old 1910 Genetics logo
The new 1910 logo
1910 typography in all its weights
1910 logo on Indigo Purple
1910 colour palette: Indigo Purple and the neutrals
1910 secondary palette: teal, mint and pink
1910 icon set
1910 ITO platform in 3D: a network of molecular nodes
1910 ITO platform in 3D: data blocks passing through a glass plane
1910 molecules in 3D: a small molecule and an antibody
1910 ITO platform in 3D: data flowing into the processor
1910 type scale, colour styles and buttons
1910 website home page
1910 website: the ITO platform page
1910 website careers page on desktop and phone
1910 website: the partnering page
1910 website: the pipeline page
1910 website on two phones: the home page and the ITO platform page
1910 ITO platform: AI-driven Molecular Design & Optimization, from input to output
1910 ITO platform: Federated Learning, three local models and one global model
1910 ITO platform: AI-driven Precision Target ID, from patient data to novel targets
1910 poster: ITO Platform is a scalable, end-to-end AI solution
1910 logo in 3D